ROTH Capital Partners Acts as Lead U.S. Placement Agent
for Pharming Group N.V. (EURONEXT: PHARM) in its
€104 Million Financing

For more information please contact:

Investment Banking
John Chambers
Vice-Chairman and
Head of Healthcare
Investment Banking

(646) 358-1901

Michael Margolis, R.Ph
Managing Director
(646) 358-1902


Warren Dunnavant II
(646) 358-1903


Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703


Nazan Akdeniz
Senior Vice President
(949) 720-5740


Lou Ellis
Senior Vice President
(949) 720-5739

Transaction Information

Pharming Group N.V. (EURONEXT: PHARM) announced that it has closed a new financing round, comprising three financial instruments and a rights issue, providing a total gross proceeds of €104 million. The financing will be used to pay the upfront amount of US$60 million (approximately €56.1 million) to acquire the commercialization rights to its own high quality Hereditary Angioedema therapy RUCONEST® in North America. Additionally, the proceeds of the financing will be used to boost sales of RUCONEST® in North America as well as in the additional countries in Western Europe and the Middle East in which Pharming is selling the product directly. The €104 million financing includes convertible notes, new senior notes, and proceeds of a rights offering.


ROTH Capital Partners acted as Lead U.S. Placement Agent in the transactions.


About Pharming Group N.V.

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. For more Information, please visit (Source: Company Press Release | 12.7.16)


About ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S.  For more information on ROTH, please visit

About ROTH Investment Banking Venture Finance Institutional Sales & Trading
Research Corporate Services Marketing & Conferences Press Room

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2017.